TXMD / TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q1 2022 Results - Earnings Call Transcript

TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive more_horizontal

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbe more_horizontal

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare co more_horizontal

Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority o more_horizontal

Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Hea more_horizontal

TherapeuticsMD's $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercializa more_horizontal

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily s more_horizontal

TherapeuticsMD, Inc. (NASDAQ: TXMD) announced it entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners a more_horizontal